Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Digital Technology for Monitoring Adherence to Inhaled Therapies in People With Cystic Fibrosis." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440393/all/Vitamin_E_for_people_with_non‐alcoholic_fatty_liver_disease_New. Accessed 26 April 2024.
Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440393/all/Vitamin_E_for_people_with_non‐alcoholic_fatty_liver_disease_New. Accessed April 26, 2024.
Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/440393/all/Vitamin_E_for_people_with_non‐alcoholic_fatty_liver_disease_New
Digital Technology for Monitoring Adherence to Inhaled Therapies in People With Cystic Fibrosis [Internet]. In: Cochrane Abstracts. [cited 2024 April 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440393/all/Vitamin_E_for_people_with_non‐alcoholic_fatty_liver_disease_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis
ID - 440393
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440393/all/Vitamin_E_for_people_with_non‐alcoholic_fatty_liver_disease_New
DB - Evidence Central
DP - Unbound Medicine
ER -